Jacqueline M. Miller

8.2k total citations · 2 hit papers
97 papers, 2.6k citations indexed

About

Jacqueline M. Miller is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Jacqueline M. Miller has authored 97 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Epidemiology, 49 papers in Microbiology and 28 papers in Infectious Diseases. Recurrent topics in Jacqueline M. Miller's work include Bacterial Infections and Vaccines (49 papers), Pneumonia and Respiratory Infections (43 papers) and Influenza Virus Research Studies (33 papers). Jacqueline M. Miller is often cited by papers focused on Bacterial Infections and Vaccines (49 papers), Pneumonia and Respiratory Infections (43 papers) and Influenza Virus Research Studies (33 papers). Jacqueline M. Miller collaborates with scholars based in United States, Belgium and India. Jacqueline M. Miller's co-authors include Véronique Bianco, Marie Van der Wielen, Yaela Baine, Kosta Y. Mumcuoğlu, Michael Friger, Dominique Boutriau, Mark Tarshis, Bethany Girard, Rituparna Das and Lindsey R. Baden and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jacqueline M. Miller

92 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

2022 346 citations Spyros Chalkias, Brandon Essink et al. profile →
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults

2025 18 citations Mieke Soens, Jintanat Ananworanich et al. Vaccine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacqueline M. Miller United States	27	1.2k	1.0k	780	271	262	97	2.6k
Karen Rudolph United States	26	1.6k 1.4×	739 0.7×	494 0.6×	427 1.6×	83 0.3×	68	2.6k
Vasanthi Avadhanula United States	21	960 0.8×	153 0.2×	651 0.8×	197 0.7×	58 0.2×	60	1.7k
Heidi Wood Canada	19	444 0.4×	565 0.6×	735 0.9×	259 1.0×	31 0.1×	56	1.7k
Rebecca Howell‐Jones United Kingdom	19	2.1k 1.7×	459 0.5×	153 0.2×	400 1.5×	57 0.2×	36	2.7k
Li Deng United States	23	852 0.7×	91 0.1×	529 0.7×	302 1.1×	146 0.6×	86	1.7k
John Watson United Kingdom	29	1.5k 1.2×	106 0.1×	863 1.1×	360 1.3×	332 1.3×	90	2.9k
Charu Kaushic Canada	34	1.2k 1.0×	1.1k 1.1×	592 0.8×	502 1.9×	30 0.1×	91	3.8k
Jason M. Mwenda Republic of the Congo	32	394 0.3×	165 0.2×	1.7k 2.2×	141 0.5×	134 0.5×	189	3.6k
Renata J.M. Engler United States	21	439 0.4×	39 0.0×	779 1.0×	283 1.0×	172 0.7×	72	2.2k

Countries citing papers authored by Jacqueline M. Miller

Since Specialization

Citations

This map shows the geographic impact of Jacqueline M. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline M. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline M. Miller more than expected).

Fields of papers citing papers by Jacqueline M. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline M. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline M. Miller. The network helps show where Jacqueline M. Miller may publish in the future.

Co-authorship network of co-authors of Jacqueline M. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline M. Miller. A scholar is included among the top collaborators of Jacqueline M. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline M. Miller. Jacqueline M. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soens, Mieke, Jintanat Ananworanich, Kathryn Jean Lucas, et al.. (2025). A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine. 50. 126847–126847. 18 indexed citations breakdown →

Goswami, Jaya, José F. Cardona, Denise C. Hsu, et al.. (2024). Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. The Lancet Infectious Diseases. 25(4). 411–423. 11 indexed citations

Priddy, Frances, Spyros Chalkias, Brandon Essink, et al.. (2024). A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children. Expert Review of Vaccines. 23(1). 862–878. 6 indexed citations

Figueroa, Amparo L., Jamil Azzi, Bijan Eghtesad, et al.. (2024). Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. The Journal of Infectious Diseases. 230(3). e591–e600. 3 indexed citations

Panther, Lori, Carlos Fierro, Daniel C. Brune, et al.. (2023). 2892. Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial. Open Forum Infectious Diseases. 10(Supplement_2). 15 indexed citations

Follmann, Dean, Holly Janes, Olive D. Buhule, et al.. (2022). Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of Internal Medicine. 175(9). 1258–1265. 69 indexed citations

Booy, Robert, Terry Nolan, Graham Reynolds, et al.. (2015). Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers. The Pediatric Infectious Disease Journal. 34(12). 1379–1384. 3 indexed citations

Zafra, Christina L. Zuch de, Cindy Farman, Eric Wakshull, et al.. (2015). Repeat-dose intravitreal administration of a humanized monoclonal antibody is poorly tolerated in rabbits. Investigative Ophthalmology & Visual Science. 56(7). 3640–3640. 1 indexed citations

Blatter, Mark M., et al.. (2014). Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae–N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy. Vaccine. 33(7). 933–941. 6 indexed citations

10.

Stiell, Ian G., et al.. (2014). Multicentre Implementation of the Canadian C-spine Rule by Emergency Department Triage Nurses: 795. Academic Emergency Medicine. 21. 2 indexed citations

11.

Torres, Juan Carlos Tejedor, José Merino, Manuel Moro, et al.. (2012). Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine. The Pediatric Infectious Disease Journal. 31(10). 1074–1077. 5 indexed citations

12.

Dbaibo, Ghassan, et al.. (2012). The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. International Journal of Infectious Diseases. 16(8). e608–e615. 19 indexed citations

13.

Dimaano, Efren M., et al.. (2012). The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Human Vaccines & Immunotherapeutics. 8(7). 881–887. 21 indexed citations

14.

Nolan, Terry, Peter Richmond, Helen Marshall, et al.. (2010). Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine. The Pediatric Infectious Disease Journal. 30(3). 190–196. 21 indexed citations

15.

Baxter, Roger, Yaela Baine, Kathleen Ensor, et al.. (2010). Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age. The Pediatric Infectious Disease Journal. 30(3). e41–e48. 55 indexed citations

16.

Østergaard, Lars, Véronique Bianco, Marie Van der Wielen, & Jacqueline M. Miller. (2010). 530 Persistence of Immune Response to Candidate Meningococcal Serogroups A, C, W-135, Y Tetanus Toxoid-Conjugated Vaccine (MenACWY-TT) up to 42 Months Following Primary Vaccination. Pediatric Research. 68. 270–271. 4 indexed citations

17.

Bueger, Christian, P. Elliott Miller, Catherine J. Murphy, et al.. (2006). Safety Evaluation of Intravitreal Administration of VEGF Trap in Cynomolgus Monkeys for 13 Weeks. Investigative Ophthalmology & Visual Science. 47(13). 1751–1751. 4 indexed citations

18.

Heaton, Penny M., Michelle G. Goveia, Jacqueline M. Miller, Paul A. Offit, & H. F. Clark. (2005). Development of a Pentavalent Rotavirus Vaccine against Prevalent Serotypes of Rotavirus Gastroenteritis. The Journal of Infectious Diseases. 192(s1). S17–S21. 66 indexed citations

19.

McCann, Judith J., Liesi E. Hebert, Li Y, et al.. (2005). The Effect of Adult Day Care Services on Time to Nursing Home Placement in Older Adults With Alzheimer's Disease. The Gerontologist. 45(6). 754–763. 80 indexed citations

20.

Miller, Jacqueline M., et al.. (1980). Effect of an R Plasmid on the Virulence of a Hospital Strain of <i>Escherichia col</i><i>i</i>. Chemotherapy. 26(6). 427–430. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact